EATONTOWN, N.J., Nov. 2 /PRNewswire/ -- Roberts Pharmaceutical Corporation
(Amex: RPC) announced today that it has initiated a multi-phase upgrade
program to expand significantly the online information and services available
from the Company through its internet home page at http://www.robertspharm.com.
As part of the first phase of this upgrade, Roberts said its website now
offers a complete investor relations package. This includes: an archive of
news releases; a broad range of financial data; a list of brokerage firms and
analysts who cover the Company; consensus earnings estimates; and both current
and historical stock price information.
Additionally, the Company's SEC filings may be downloaded directly from
the Roberts website and an interactive calendar is available which individuals
can use to be reminded by email of scheduled Company events and presentations.
Roberts said it plans other changes and additions to its website which
will encompass a significant broadening of the information and services
available online with regard to the Company's products, new drug development
programs, international operations, and more.
"The number of people connected to the worldwide web increases everyday,"
said Roberts' Director of Investor Relations, Stuart Z. Levine, Ph.D.
"Utilizing our website to build a bigger, more functional presence on the
internet is consistent with our commitment to maintaining strong channels of
communications for our customers, medical professionals, investors, and anyone
interested in knowing more about Roberts."
Roberts Pharmaceutical Corporation, with operating subsidiaries in the
United States, Canada and the United Kingdom, focuses on innovative and
value-added therapeutics for gastroenterology, cardiology, neurology,
oncology/hematology, and urology. Roberts actively pursues its strategy of
"Search & Develop" to identify and acquire novel drug candidates to advance
through late-stage development into the market while also pursuing
opportunities to acquire and bring commercially available specialty
pharmaceuticals to their full potential.
This and past press releases of Roberts Pharmaceutical Corporation are
available through PR Newswire's Company News On Call fax service at
800-758-5804, extension 760975 and through the internet at
http://www.prnewswire.com as well as the Company's home page at
http://www.robertspharm.com.
This release may contain forward-looking statements which are based on
assumptions and external factors, including assumptions relating to, but not
limited to regulatory action, product pricing, competitive market conditions,
financial data, new product development and other risks or uncertainties
detailed from time to time in Roberts filings with the Securities and Exchange
Commission. These forward-looking statements represent the Company's judgment
as of the date of this release and any changes in the assumptions or external
factors could produce significantly different results.
SOURCE Roberts Pharmaceutical Corporation
 back to top
Related links:
http://www.robertspharm.com
Company News On-Call:
http://www.prnewswire.com/comp/760975.html or fax,
800-758-5804, ext. 760975
CONTACT:
Stuart Z. Levine, Ph.D., Director of Investor
Relations of Roberts Pharmaceutical, 732-676-1200, ext. 3064
|
